Tag: AbbVie

In a landmark advancement for patients with ultra-rare blood cancers, the U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine (Decnupaz™; AbbVie), previously known as IMGN632, marking the first and only antibody-drug conjugate (ADC) authorized for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company History

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

Engineering the Future of Cancer Care: How Next-Generation Antibody-Drug Conjugates (ADCs) Are Shaping Oncology and Beyond

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399; See Drug description and ADC Drugmap)*, a c-Met-directed antibody-drug conjugates (ADC) for ther treatment of adults patients diagnosed with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein over-expression who received a prior systemic therapy.

What to Expect at World ADC 2024 in London

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...